share_log

Granahan Investment Management LLC Increases Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

Granahan Investment Management LLC Increases Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

格蘭納漢投資管理公司增加在生物生命解決方案公司(納斯達克市場代碼：BLFS)的地位
Defense World ·  2022/09/10 04:51

Granahan Investment Management LLC lifted its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) by 40.3% during the first quarter, Holdings Channel.com reports. The institutional investor owned 609,604 shares of the medical equipment provider's stock after acquiring an additional 175,172 shares during the quarter. Granahan Investment Management LLC's holdings in BioLife Solutions were worth $13,856,000 as of its most recent filing with the Securities & Exchange Commission.

據Holdings Channel.com報道，Granahan Investment Management LLC在第一季度增持了生物生命解決方案公司(BLFS-GET Rating)40.3%的股份。該機構投資者在本季度額外收購了175,172股後，持有這家醫療設備提供商的609,604股股票。截至最近提交給證券交易委員會的文件，Granahan Investment Management LLC在BioLife Solutions持有的股份價值13,856,000美元。

A number of other hedge funds and other institutional investors have also recently modified their holdings of BLFS. Ranger Investment Management L.P. lifted its stake in BioLife Solutions by 43.0% in the fourth quarter. Ranger Investment Management L.P. now owns 1,255,260 shares of the medical equipment provider's stock valued at $46,784,000 after purchasing an additional 377,358 shares during the last quarter. Invesco Ltd. raised its holdings in BioLife Solutions by 26.9% during the 4th quarter. Invesco Ltd. now owns 769,736 shares of the medical equipment provider's stock valued at $28,688,000 after acquiring an additional 163,176 shares during the period. Barings LLC bought a new stake in BioLife Solutions during the 1st quarter valued at $2,076,000. JPMorgan Chase & Co. raised its holdings in BioLife Solutions by 20.9% during the 4th quarter. JPMorgan Chase & Co. now owns 471,575 shares of the medical equipment provider's stock valued at $17,576,000 after acquiring an additional 81,435 shares during the period. Finally, Nuveen Asset Management LLC raised its holdings in BioLife Solutions by 25.8% during the 4th quarter. Nuveen Asset Management LLC now owns 377,764 shares of the medical equipment provider's stock valued at $14,079,000 after acquiring an additional 77,364 shares during the period. Hedge funds and other institutional investors own 86.69% of the company's stock.

許多其他對衝基金和其他機構投資者最近也調整了對BLFS的持股。Ranger Investment Management L.P.在第四季度增持了BioLife Solutions 43.0%的股份。Ranger Investment Management L.P.在上個季度額外購買了377,358股票後，現在擁有這家醫療設備提供商1,255,260股票，價值46,784,000美元。景順有限公司在第四季度增持了26.9%的BioLife Solutions股份。景順公司目前持有這家醫療設備供應商的769,736股股票，價值28,688,000美元，在此期間又購入了163,176股。霸菱有限責任公司在第一季度購買了BioLife Solutions的新股份，價值2,076,000美元。摩根大通在第四季度增持了BioLife Solutions的股份20.9%。摩根大通(JPMorgan Chase&Co.)在此期間增持了81,435股，目前持有這家醫療設備供應商471,575股，價值17,576,000美元。最後，Nuveen Asset Management LLC在第四季度將其在BioLife Solutions的持股增加了25.8%。Nuveen Asset Management LLC在此期間額外收購了77,364股票，目前擁有這家醫療設備提供商377,764股票，價值14,079,000美元。對衝基金和其他機構投資者持有該公司86.69%的股票。

Get
到達
BioLife Solutions
生物生命解決方案
alerts:
警報：

BioLife Solutions Trading Down 0.3 %

BioLife Solutions股價下跌0.3%

BioLife Solutions stock opened at $26.62 on Friday. The stock has a market cap of $1.13 billion, a P/E ratio of -11.83 and a beta of 1.91. BioLife Solutions, Inc. has a fifty-two week low of $10.40 and a fifty-two week high of $58.80. The firm's fifty day moving average price is $20.70 and its 200-day moving average price is $18.39. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.54 and a current ratio of 3.55.

BioLife Solutions的股票週五開盤報26.62美元。該股市值為11.3億美元，市盈率為-11.83，貝塔係數為1.91。BioLife Solutions，Inc.的股價為52周低點10.40美元，52周高點為58.80美元。該公司的50日移動均線價格為20.70美元，200日移動均線價格為18.39美元。該公司的負債權益比為0.02，速動比率為2.54，流動比率為3.55。

Insider Transactions at BioLife Solutions

BioLife Solutions的內幕交易

In other news, CRO Marcus Schulz sold 4,600 shares of the company's stock in a transaction on Wednesday, August 3rd. The shares were sold at an average price of $20.03, for a total value of $92,138.00. Following the transaction, the executive now owns 36,218 shares of the company's stock, valued at $725,446.54. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other BioLife Solutions news, COO Greef Roderick De sold 9,158 shares of the company's stock in a transaction dated Tuesday, July 12th. The shares were sold at an average price of $15.79, for a total transaction of $144,604.82. Following the completion of the sale, the chief operating officer now directly owns 124,458 shares in the company, valued at $1,965,191.82. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CRO Marcus Schulz sold 4,600 shares of the company's stock in a transaction dated Wednesday, August 3rd. The shares were sold at an average price of $20.03, for a total transaction of $92,138.00. Following the sale, the executive now owns 36,218 shares of the company's stock, valued at $725,446.54. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,401 shares of company stock valued at $313,764. 3.30% of the stock is currently owned by company insiders.
在其他新聞方面，CRO馬庫斯·舒爾茨在8月3日星期三的一筆交易中出售了4600股該公司股票。這些股票的平均價格為20.03美元，總價值為92,138.00美元。交易完成後，這位高管現在持有該公司36,218股股票，價值725,446.54美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可在美國證券交易委員會網站上查閲。在BioLife Solutions的其他消息中，首席運營官格里夫·羅德里克·德在7月12日(星期二)的交易中出售了9158股該公司股票。這些股票以15.79美元的平均價格出售，總成交金額為144,604.82美元。出售完成後，首席運營官現在直接擁有該公司124,458股，價值1,965,191.82美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，可以通過這個鏈接訪問。此外，CRO馬庫斯·舒爾茨在日期為8月3日(星期三)的交易中出售了4600股該公司股票。這些股票以20.03美元的平均價格出售，總成交金額為92,138.00美元。出售後，這位高管現在持有該公司36,218股股票，價值725,446.54美元。此次拍賣的披露信息可在此處找到。在上個季度，內部人士出售了18,401股公司股票，價值313,764美元。3.30%的股份目前由公司內部人士持有。

Wall Street Analysts Forecast Growth

華爾街分析師預測經濟增長

BLFS has been the topic of a number of analyst reports. B. Riley lowered their target price on shares of BioLife Solutions from $48.00 to $34.00 in a report on Tuesday, May 17th. Cowen lowered their target price on shares of BioLife Solutions to $29.00 in a report on Monday, August 15th. One equities research analyst has rated the stock with a sell rating and three have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $31.25.

BLFS一直是許多分析師報告的主題。B.萊利在5月17日星期二的一份報告中將BioLife Solutions的目標價從48.00美元下調至34.00美元。考恩在8月15日星期一的一份報告中將BioLife Solutions的目標價下調至29.00美元。一位股票研究分析師將該股的評級定為賣出，三位分析師將其評級定為買入。根據MarketBeat的數據，該公司的平均評級為“中等買入”，平均目標價為31.25美元。

BioLife Solutions Company Profile

BioLife Solutions公司簡介

(Get Rating)

(獲取評級)

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

BioLife Solutions，Inc.為美國、加拿大、歐洲、中東、非洲和國際上的細胞和基因治療行業開發、製造和提供生物生產工具和服務。該公司的產品用於基礎和應用研究，以及基於生物的療法的商業製造。

Further Reading

進一步閲讀

  • Get a free copy of the StockNews.com research report on BioLife Solutions (BLFS)
  • MarketBeat: Week in Review 9/5 – 9/9
  • Prepare For A Record-Setting Quarter For Cyber Security Stocks
  • The Auto Market Is Slowly Recovering, These Stocks May Outperform
  • Is DocuSign On The Verge Of A Major Reversal?
  • Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
  • 免費獲取StockNews.com關於BioLife解決方案的研究報告(BLFS)
  • MarketBeat：回顧一週9/5-9/9
  • 為網絡安全股創紀錄的季度做準備
  • 汽車市場正在緩慢復甦，這些股票可能表現優異
  • DocuSign是否即將發生重大逆轉？
  • 石油和天然氣股票：投資可再生能源的安全途徑

Want to see what other hedge funds are holding BLFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating).

想看看還有哪些對衝基金持有BLFS嗎？訪問HoldingsChannel.com獲取BioLife Solutions，Inc.(納斯達克代碼：BLFS-GET Rating)的最新13F備案文件和內幕交易信息。

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

每日收到有關BioLife解決方案的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對BioLife Solutions和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論